Boston-based clinical-stage biotech developing precision therapies for autoimmune and inflammatory diseases. Emerged from stealth with five programs licensed from Bristol Myers Squibb, including Phase 2 lupus candidate afimetoran and novel IL-2 assets. Led by CEO Saqib Islam, who previously guided Pfizer's immunology portfolio. Focuses on precision immunology — targeting the right patients with the right therapy at the right time.
1
Round
4
Tags
Apr 17, 2026
Latest raise
Funding activity · 1 round
Apr 17, 2026
$300M
Series A
Led by Bain Capital
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
